Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficiency of adding pioglitazone to chronic phase chronic myelogenous leukemia patients having received imatinib mesylate who have acquired a stable molecular response but not complete molecular response.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Meng Li
• Treatments: Imatinib Mesylate; Pioglitazone

Criteria

Inclusion Criteria:

1. Signed informed consent.

2. Treatment with imatinib mesylate for more than 2 years.

3. Patients with chronic phase chronic myelogenous leukemia having a complete cytogenetic response and a stable molecular response without complete molecular response.

4. Normal important organs such as kidney, liver and heart.

Exclusion Criteria:

1. Severe important organs disfunction such as liver and kidney.

2. Cardiovascular disease.

3. Osteoporosis in therapy.

4. Severe fluid retention.